Cargando…

Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction

Angiotensin receptor-neprilysin inhibitor (ARNI) and sodium–glucose co-transporter-2 inhibitor (SGLT2i) have shown benefits in diabetic patients with heart failure with reduced ejection fraction (HFrEF). However, their combined effect has not been revealed. We retrospectively identified diabetic pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyue Mee, Hwang, In-Chang, Choi, Wonsuk, Yoon, Yeonyee E., Cho, Goo-Yeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595580/ https://www.ncbi.nlm.nih.gov/pubmed/34785723 http://dx.doi.org/10.1038/s41598-021-01759-5

Ejemplares similares

SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis
por: Yan, Yuling, et al.
Publicado: (2021)

Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction
por: Moon, Mi‐Gil, et al.
Publicado: (2021)

Will introduction of ARNI reduce the need of device therapy in heart failure with reduced ejection fraction?
por: Kaur, Navjyot, et al.
Publicado: (2021)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Global Benefit of SGLT2 Inhibitors in Heart Failure With Reduced Ejection Fraction
por: Brownell, Nicholas K., et al.
Publicado: (2022)

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
por: Clemmer, John S., et al.
Publicado: (2023)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
por: Jariwala, Pankaj, et al.
Publicado: (2021)

Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
por: Hwang, In-Chang, et al.
Publicado: (2020)

Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
por: Heath, Rebecca, et al.
Publicado: (2022)

Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction
por: Pabel, Steffen, et al.
Publicado: (2021)

Impact of SGLT2 Inhibitor Therapy on Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2022)

Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register
por: Pastore, Maria Concetta, et al.
Publicado: (2021)

Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension
por: Kim, Hyue Mee, et al.
Publicado: (2022)

EMPEROR-Preserved: SGLT2 inhibitors breakthrough in the management of heart failure with preserved ejection fraction
por: Wagdy, Kerolos, et al.
Publicado: (2021)

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
por: Genuardi, Michael V., et al.
Publicado: (2021)

Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction
por: Fu, Michael, et al.
Publicado: (2022)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Jiang, Yaohui, et al.
Publicado: (2021)

Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review
por: Jhalani, Nisha B.
Publicado: (2022)

Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
por: De Lorenzi, Andrea Beatriz, et al.
Publicado: (2023)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Efficacy of sacubitril‐valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta‐analysis
por: Mo, Xingchun, et al.
Publicado: (2023)

Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction
por: Alcidi, Gianmarco, et al.
Publicado: (2023)

Myocardial strain for heart failure with preserved ejection fraction but without diastolic dysfunction
por: Park, Jin Joo, et al.
Publicado: (2022)

Left Ventricular Systolic Function After 3 Months of SGLT2 Inhibitor Therapy in Heart Failure Patients with Reduced Ejection Fraction
por: Mustapic, Ivona, et al.
Publicado: (2023)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
por: Lu, He, et al.
Publicado: (2023)

SGLT2i‑treated heart failure patients with a reduced ejection fraction: A meta‑analysis
por: Ye, Qiang, et al.
Publicado: (2023)

ARNI and SGLT2i: a promising association to be used with caution
por: Herbst, Andrea, et al.
Publicado: (2020)

Response to cardiac resynchronization therapy and treatment with ARNi and iSGLT2
por: Fonderico, C, et al.
Publicado: (2023)

Angiotensin Receptor-Neprilysin Inhibition (ARNI) in Heart Failure
por: Greenberg, Barry
Publicado: (2020)

Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021–2022: an analysis of real-world data
por: Alonso, Alvaro, et al.
Publicado: (2023)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes
por: Park, Jin Joo, et al.
Publicado: (2020)

Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial
por: Kristensen, Søren L., et al.
Publicado: (2016)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
por: Park, Su Yeong, et al.
Publicado: (2023)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
por: Malik, Jahanzeb, et al.
Publicado: (2021)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_05btuhmgkh051he4gl52d523jt